End stage hip disease
Conditions
Interventions
Intravenous dexamethasone group:intravenous dexamethasone 10 mg before surgery
Intravenous combined with topical dexamethasone group:intravenous and topical dexamethasone
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients requiring primary total hip arthroplasty due to severe hip osteoarthritis, femoral head necrosis, and secondary osteoarthritis due to developmental hip dysplasia; 2.Aged between 20 and 80 years; 3.Body mass index is between 20 and 35 kg/m2; 4.The American Society of Anesthesiologists (American Society of Anesthesiologists, ASA) classification (anesthesia risk assessment) I to III level.
Exclusion criteria
Exclusion criteria: 1.Simultaneous operation of both hip joints; 2.Patients with blood diseases, diabetes, malignant tumors and abnormal coagulation function; 3.Patients with a history of myocardial infarction, cerebral infarction, pulmonary embolism and other thrombosis; 4.Those who received anticoagulant therapy within 6 months before operation; 5.Persons with severe hip malformation and previous history of hip surgery; 6.Persons allergic to narcotic drugs and sulfanilamide; 7.Alcoholism or long-term use of opioids; 8.Language impairment and inability to complete Visual analogue Scale (VAS); 9.Surgical limb neuropathy; 10.Mentally ill; 11.Patients with digestive tract ulcer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative dosage of remedial morphine hydrochloride;VAS pain score;hip range of motion;inflammatory indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| nausea and vomiting;blood routine examination;Harris hip score; | — |
Countries
China
Contacts
Public ContactKang Pengde
Department of Orthopaedics Surgery, West China Hospital of Sichuan University
Outcome results
None listed